

<!DOCTYPE html>
<html lang="zh-CN" >



<head>
  <meta charset="UTF-8">

  <link rel="apple-touch-icon" sizes="76x76" href="/img/Logo.png">
  <link rel="icon" href="/img/Logo.png">
  

  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0, shrink-to-fit=no">
  <meta http-equiv="x-ua-compatible" content="ie=edge">
  
  <meta name="theme-color" content="#2f4154">
  <meta name="author" content="向海">
  <meta name="keywords" content="">
  
    <meta name="description" content="Therapy and drugs for cancer">
<meta property="og:type" content="article">
<meta property="og:title" content="L14 Cancer Pharmacology">
<meta property="og:url" content="https://zhenyumi.github.io/posts/6c8073ce/index.html">
<meta property="og:site_name" content="鹘横海">
<meta property="og:description" content="Therapy and drugs for cancer">
<meta property="og:locale" content="zh_CN">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202224854.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202242643.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202347631.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202624981.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202634016.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202727564.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202748270.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203057109.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203121832.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203413169.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203426462.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203721454.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203946159.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204007399.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204012617.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204127022.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204921275.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204932275.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135050395.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135059029.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135104615.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135120792.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525141253371.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525141330998.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142139737.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142258974.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142315443.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142322670.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143532638.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143608863.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143659938.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143741516.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143752339.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143843235.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164029948.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164043950.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164053841.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164345230.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164941329.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164949067.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170126311.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170148030.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170709521.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525171044816.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172442824.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172655578.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172934902.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172950715.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173019126.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173032440.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173303528.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173917874.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525174006082.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525174038754.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175114183.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175240334.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525152058913.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175504627.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175644835.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175715808.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175724146.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175734353.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175742320.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175753074.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184614504.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184705780.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184756462.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184908253.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184957613.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185018602.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185127839.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185145400.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185258096.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185414485.png">
<meta property="og:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185436414.png">
<meta property="article:published_time" content="2021-06-01T07:47:14.000Z">
<meta property="article:modified_time" content="2021-06-01T07:47:14.000Z">
<meta property="article:author" content="向海">
<meta property="article:tag" content="Molecular Pharmacology">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:image" content="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202224854.png">
  
  
  
  <title>L14 Cancer Pharmacology - 鹘横海</title>

  <link  rel="stylesheet" href="https://lib.baomitu.com/twitter-bootstrap/4.6.1/css/bootstrap.min.css" />



  <link  rel="stylesheet" href="https://lib.baomitu.com/github-markdown-css/4.0.0/github-markdown.min.css" />

  <link  rel="stylesheet" href="https://lib.baomitu.com/hint.css/2.7.0/hint.min.css" />

  <link  rel="stylesheet" href="https://lib.baomitu.com/fancybox/3.5.7/jquery.fancybox.min.css" />



<!-- 主题依赖的图标库，不要自行修改 -->
<!-- Do not modify the link that theme dependent icons -->

<link rel="stylesheet" href="//at.alicdn.com/t/c/font_1749284_5i9bdhy70f8.css">



<link rel="stylesheet" href="//at.alicdn.com/t/c/font_1736178_k526ubmyhba.css">


<link  rel="stylesheet" href="/css/main.css" />


  <link id="highlight-css" rel="stylesheet" href="/css/highlight.css" />
  




  <script id="fluid-configs">
    var Fluid = window.Fluid || {};
    Fluid.ctx = Object.assign({}, Fluid.ctx)
    var CONFIG = {"hostname":"zhenyumi.github.io","root":"/","version":"1.9.8","typing":{"enable":true,"typeSpeed":70,"cursorChar":"_","loop":false,"scope":["home"]},"anchorjs":{"enable":true,"element":"h1,h2,h3,h4,h5,h6","placement":"left","visible":"hover","icon":""},"progressbar":{"enable":true,"height_px":3,"color":"#29d","options":{"showSpinner":false,"trickleSpeed":100}},"code_language":{"enable":true,"default":"TEXT"},"copy_btn":true,"image_caption":{"enable":true},"image_zoom":{"enable":true,"img_url_replace":["",""]},"toc":{"enable":true,"placement":"right","headingSelector":"h1,h2,h3,h4,h5,h6","collapseDepth":0},"lazyload":{"enable":true,"loading_img":"/img/loading.gif","onlypost":false,"offset_factor":2},"web_analytics":{"enable":false,"follow_dnt":true,"baidu":null,"google":{"measurement_id":null},"tencent":{"sid":null,"cid":null},"leancloud":{"app_id":null,"app_key":null,"server_url":null,"path":"window.location.pathname","ignore_local":false},"umami":{"src":null,"website_id":null,"domains":null,"start_time":"2024-01-01T00:00:00.000Z","token":null,"api_server":null}},"search_path":"/local-search.xml","include_content_in_search":true};

    if (CONFIG.web_analytics.follow_dnt) {
      var dntVal = navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack;
      Fluid.ctx.dnt = dntVal && (dntVal.startsWith('1') || dntVal.startsWith('yes') || dntVal.startsWith('on'));
    }
  </script>
  <script  src="/js/utils.js" ></script>
  <script  src="/js/color-schema.js" ></script>
  


  
<meta name="generator" content="Hexo 7.0.0"></head>


<body>
  

  <header>
    

<div class="header-inner" style="height: 70vh;">
  <nav id="navbar" class="navbar fixed-top  navbar-expand-lg navbar-dark scrolling-navbar">
  <div class="container">
    <a class="navbar-brand" href="/">
      <strong>鹘横海</strong>
    </a>

    <button id="navbar-toggler-btn" class="navbar-toggler" type="button" data-toggle="collapse"
            data-target="#navbarSupportedContent"
            aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
      <div class="animated-icon"><span></span><span></span><span></span></div>
    </button>

    <!-- Collapsible content -->
    <div class="collapse navbar-collapse" id="navbarSupportedContent">
      <ul class="navbar-nav ml-auto text-center">
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/" target="_self">
                <i class="iconfont icon-home-fill"></i>
                <span>首页</span>
              </a>
            </li>
          
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/archives/" target="_self">
                <i class="iconfont icon-archive-fill"></i>
                <span>归档</span>
              </a>
            </li>
          
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/categories/" target="_self">
                <i class="iconfont icon-category-fill"></i>
                <span>分类</span>
              </a>
            </li>
          
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/tags/" target="_self">
                <i class="iconfont icon-tags-fill"></i>
                <span>标签</span>
              </a>
            </li>
          
        
          
          
          
          
            <li class="nav-item">
              <a class="nav-link" href="/about/" target="_self">
                <i class="iconfont icon-user-fill"></i>
                <span>关于</span>
              </a>
            </li>
          
        
        
          <li class="nav-item" id="search-btn">
            <a class="nav-link" target="_self" href="javascript:;" data-toggle="modal" data-target="#modalSearch" aria-label="Search">
              <i class="iconfont icon-search"></i>
            </a>
          </li>
          
        
        
      </ul>
    </div>
  </div>
</nav>

  

<div id="banner" class="banner" parallax=true
     style="background: url('https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Others/Fluid/post/post2.jpg') no-repeat center center; background-size: cover;">
  <div class="full-bg-img">
    <div class="mask flex-center" style="background-color: rgba(0, 0, 0, 0.3)">
      <div class="banner-text text-center fade-in-up">
        <div class="h2">
          
            <span id="subtitle">L14 Cancer Pharmacology</span>
          
        </div>

        
          
  <div class="mt-3">
    
    
      <span class="post-meta">
        <i class="iconfont icon-date-fill" aria-hidden="true"></i>
        <time datetime="2021-06-01 15:47" pubdate>
          2021年6月1日 下午
        </time>
      </span>
    
  </div>

  <div class="mt-1">
    
      <span class="post-meta mr-2">
        <i class="iconfont icon-chart"></i>
        
          898 字
        
      </span>
    

    
      <span class="post-meta mr-2">
        <i class="iconfont icon-clock-fill"></i>
        
        
        
          8 分钟
        
      </span>
    

    
    
  </div>


        
      </div>

      
    </div>
  </div>
</div>

</div>

  </header>

  <main>
    
      

<div class="container-fluid nopadding-x">
  <div class="row nomargin-x">
    <div class="side-col d-none d-lg-block col-lg-2">
      

    </div>

    <div class="col-lg-8 nopadding-x-md">
      <div class="container nopadding-x-md" id="board-ctn">
        <div id="board">
          <article class="post-content mx-auto">
            <h1 id="seo-header">L14 Cancer Pharmacology</h1>
            
            
              <div class="markdown-body">
                
                <h1 id="一、Cancer-Biology"><a href="#一、Cancer-Biology" class="headerlink" title="一、Cancer Biology"></a>一、Cancer Biology</h1><h2 id="What-is-Cancer"><a href="#What-is-Cancer" class="headerlink" title="What is Cancer"></a>What is Cancer</h2><p>Cancer or Neoplasm is an abnormal mass of tissue as a result of abnormal proliferation of cells.</p>
<p>Neo-plasm: novel swelling mass in the body</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202224854.png" srcset="/img/loading.gif" lazyload alt="image-20210524202224854" style="zoom:100%;" />
**Some neoplasms do not form a tumor**

<ul>
<li>Some blood cancers such as leukemia don’t form a tumor, it widely spread in the bloodstream and bone marrow.</li>
</ul>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202242643.png" srcset="/img/loading.gif" lazyload alt="image-20210524202242643" style="zoom:67%;" />

<h2 id="What-are-the-difference-between-a-normal-and-cancer-cells"><a href="#What-are-the-difference-between-a-normal-and-cancer-cells" class="headerlink" title="What are the difference between a normal and cancer cells"></a>What are the difference between a normal and cancer cells</h2><h3 id="1-Cell-shape"><a href="#1-Cell-shape" class="headerlink" title="1. Cell shape"></a>1. Cell shape</h3><p>Normal cells:</p>
<ul>
<li>Committed Cells—divide only <u>a defined number of times</u>, and are <u>limited in capacity for self-renewal</u></li>
<li>Specialized Cells—carry out <strong>organ function</strong> and are incapable of cell division</li>
<li><strong>Restricted</strong> to its functional area</li>
</ul>
<p><strong>Normal and Cancer Cell Structure</strong>:</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202347631.png" srcset="/img/loading.gif" lazyload alt="image-20210524202347631" style="zoom:100%;" />
### 2. Genetic Aberrations

<p><strong>Genetic Aberrations</strong></p>
<ul>
<li>Chromosomal Translocation</li>
<li>Chromosomal Deletion</li>
<li>Gene mutation</li>
</ul>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202624981.png" srcset="/img/loading.gif" lazyload alt="image-20210524202624981" style="zoom:100%;" />
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202634016.png" srcset="/img/loading.gif" lazyload alt="image-20210524202634016" style="zoom:100%;" />
#### Chromosomal Translocation

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202727564.png" srcset="/img/loading.gif" lazyload alt="image-20210524202727564" style="zoom:100%;" />
+ Philadelphia chromosome

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524202748270.png" srcset="/img/loading.gif" lazyload alt="image-20210524202748270" style="zoom:100%;" />
## How does cancer take place (Causes of cancer)

<ol>
<li>Sex: male&gt;women</li>
<li>Age: most cancers in people&gt; 50 YO</li>
<li>Race</li>
<li>Genetic predisposition</li>
<li>Environment - living and warking</li>
</ol>
<ul>
<li>Chemicals </li>
<li>Viruses</li>
</ul>
<ol start="6">
<li>Lifestyle—smoking, alcoholism, preserved food, BBQ…</li>
</ol>
<h3 id="1-Polluting-Environment"><a href="#1-Polluting-Environment" class="headerlink" title="1. Polluting Environment"></a>1. Polluting Environment</h3><p><strong>Ionizing radiation</strong></p>
<ul>
<li>Acute leukemia</li>
<li>Thyroid cancer</li>
<li>Breast cancer</li>
<li>Lung cancer</li>
<li>Basal cell skin cancers</li>
</ul>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203057109.png" srcset="/img/loading.gif" lazyload alt="image-20210524203057109" style="zoom:100%;" />

<p><strong>Chemical exposure:</strong></p>
<ul>
<li>azo dyes</li>
<li>aflatoxins</li>
<li>asbestos</li>
<li>benzene</li>
</ul>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203121832.png" srcset="/img/loading.gif" lazyload alt="image-20210524203121832" style="zoom:100%;" />
#### Azo Dyes

<p>synthetic colours that contain an azo group, - N&#x3D;N-, as part of the structure. Azo groups do not occur naturally</p>
<p>Azo dyes account for approximately 60-70% of all dyes used in food and textile manufacture.</p>
<p>Most colored textile and leather articles are treated with azo dyes and pigments</p>
<p>Bladder cancer (dye factory workers, Azo dye workers still have a tremendous increase in urothelial cancer</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203413169.png" srcset="/img/loading.gif" lazyload alt="image-20210524203413169" style="zoom:100%;" />
#### Oncovirus: that induce cancers

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203426462.png" srcset="/img/loading.gif" lazyload alt="image-20210524203426462" style="zoom:100%;" />

<p><strong>DNA Viruses</strong> </p>
<ul>
<li>Epstein-Barr virus → Burkitt’s lymphoma</li>
<li>Hepatitis B virus → liver cancer</li>
<li>Human papilloma viruses → cervical cancer</li>
<li>Human herpes virus-8 → Kaposi sarcoma</li>
</ul>
<p><strong>RNA Viruses</strong></p>
<ul>
<li>Human T lymphotrophic virus type 1 (<strong>HTLV-I</strong>), a retrovirus, → T-cell leukemia.</li>
<li>Hepatitis C virus → liver cancer</li>
</ul>
<h4 id="Lifestyles"><a href="#Lifestyles" class="headerlink" title="Lifestyles"></a>Lifestyles</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203721454.png" srcset="/img/loading.gif" lazyload alt="image-20210524203721454" style="zoom:100%;" />
+ Smoking
+ Alcoholism
+ Preserved food
+ BBQ

<h3 id="2-Pathogenesis-of-Neoplasia"><a href="#2-Pathogenesis-of-Neoplasia" class="headerlink" title="2. Pathogenesis of Neoplasia"></a>2. Pathogenesis of Neoplasia</h3><p>Cancer development can begin with a brief exposure (hours or days) to a chemical into an activated form and the chemical need not be present ever again</p>
<p>However, DNA is altered via mutagens including chemical carcinogens, viruses, and radiation. This mutations is inherted by at least one cell division (intiation).</p>
<p>This mutation mainly lead to activation of proto-oncogene into oncogenes (leading to uncontrolled cell proliferation) and&#x2F;or inactivation of tumor suppressor genes (leading to resistance to apoptosis.)</p>
<p>Upon exposure to other epigenetic factors (hormones, cocarcinogens, immunosuppressant…which themselves are non carcinogenic) tumor growth is promoted (promotion)</p>
<h4 id="Initiation"><a href="#Initiation" class="headerlink" title="Initiation"></a>Initiation</h4><p>Initiation point at which an irreversible alteration, usually genetic, is introduced into a target cell</p>
<p>Initiation:</p>
<ol>
<li>is essentially irreversible</li>
<li>caused only by carcinogenic compounds</li>
<li>occurs rapidly after carcinogen exposure</li>
<li>alone does not result in tumor formation</li>
</ol>
<h4 id="Promotion"><a href="#Promotion" class="headerlink" title="Promotion"></a>Promotion</h4><p>Promotion is the process whereby an initiated tissue or organ develop focal proliferations and it requires the presence of continuous stimulation.</p>
<p>Promotion:</p>
<ol>
<li>reversible</li>
<li>acts only after exposure to an initiating agent</li>
<li>requires repeated administration of a promoter</li>
<li>is not carcinogenic in itself</li>
</ol>
<hr>
<p>Etiology and Pathogenesis of Neoplasia Initiation and Promotion</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524203946159.png" srcset="/img/loading.gif" lazyload alt="image-20210524203946159" style="zoom:100%;" />

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204007399.png" srcset="/img/loading.gif" lazyload alt="image-20210524204007399" style="zoom:100%;" />

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204012617.png" srcset="/img/loading.gif" lazyload alt="image-20210524204012617" style="zoom:100%;" />
# 二、Principle and strategy for cancer therapy

<h2 id="Cancer-Therapeutic-Modalities"><a href="#Cancer-Therapeutic-Modalities" class="headerlink" title="Cancer Therapeutic Modalities"></a>Cancer Therapeutic Modalities</h2><table>
<thead>
<tr>
<th>Name</th>
<th>Detail</th>
</tr>
</thead>
<tbody><tr>
<td>Surgery</td>
<td>Isolated <strong>solid</strong> cancers</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>Almost <strong>all cases,</strong> in combined with other treatments. It alone cure 10-15% of all patients.</td>
</tr>
<tr>
<td>Radiation therapy</td>
<td>Used for <strong>half of all cases</strong> to either cure or improve the symptoms of cancer.</td>
</tr>
<tr>
<td>Palliative care</td>
<td>Symptom management</td>
</tr>
</tbody></table>
<h2 id="The-log-kill-hypothesis"><a href="#The-log-kill-hypothesis" class="headerlink" title="The log-kill hypothesis"></a>The log-kill hypothesis</h2><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204127022.png" srcset="/img/loading.gif" lazyload alt="image-20210524204127022" style="zoom:100%;" />
+ Infrequent scheduling of treatment courses with low (1 log kill) dosing and a late start prolongs survival but does not cure the patient (i.e., kill rate < growth rate)
+ More intensive and frequent treatment, with adequate (2 log kill) dosing and an earlier start is successful (i.e., kill rate > growth rate)
+ Early surgical removal of the primary tumour decreases the tumour burden. Chemotherapy will remove persistant secondary tumours, and the total duration of therapy does not have to be as long as when chemotherapy alone is used.

<h2 id="Treatment-strategies"><a href="#Treatment-strategies" class="headerlink" title="Treatment strategies"></a>Treatment strategies</h2><p>Surgery + Radiotherapy + Chemotherapy</p>
<p>Combined Chemotherapy: various classes of drugs in combination </p>
<ul>
<li><strong>MP</strong>: Melphalan, prednisone </li>
<li><strong>VAD</strong>: Vincristine, Adriamycin, dexamethasone </li>
<li><strong>CHOP</strong>: Cyclophosphomide, doxorubicin, vincristine, prednisone</li>
</ul>
<p>Correct selection of drugs in a regimen can result in decreased development of resistance, synergistic effects and decreased toxic effects.</p>
<p>Drug categories:</p>
<p><strong>Cell Cycle Specifc (CCS)</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody><tr>
<td>Antimetabolites</td>
<td>Capecitabine, Cytarabine, Fludarabine, 5-Fluorouracil, Gemcitabine</td>
</tr>
<tr>
<td>Antitumor antibiotic</td>
<td>Bleomycin</td>
</tr>
<tr>
<td>Epipodophyllotoxins</td>
<td>Etoposide, Teniposide</td>
</tr>
<tr>
<td>Taxanes</td>
<td>Docetexel, Paclitaxel</td>
</tr>
<tr>
<td>Vinca Alkaloids</td>
<td>Vinblastine, Vincristine</td>
</tr>
</tbody></table>
<p><strong>Cell Cycle NonSpecifc (CCNS)</strong></p>
<table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody><tr>
<td>Alkylating agents</td>
<td>Busulfan, Carmustine, Melphalan, Thiotepa</td>
</tr>
<tr>
<td>Anthracyclines</td>
<td>Daunorubucin, Doxorubicin, Idarubicin</td>
</tr>
<tr>
<td>Antitumor Antibiotics</td>
<td>Dactinomycin, Mtomycin</td>
</tr>
<tr>
<td>Camptothecins</td>
<td>Irinotecan</td>
</tr>
<tr>
<td>Platinum analogs</td>
<td>Cisplatin, Carboplatin</td>
</tr>
</tbody></table>
<h2 id="Problems-associated-with-chemotherapy"><a href="#Problems-associated-with-chemotherapy" class="headerlink" title="Problems associated with chemotherapy"></a>Problems associated with chemotherapy</h2><h3 id="1-Resistance-to-chemotherapy"><a href="#1-Resistance-to-chemotherapy" class="headerlink" title="1. Resistance to chemotherapy"></a>1. Resistance to chemotherapy</h3><p><strong>Resistance to chemotherapy may develop by several mechanisms:</strong> </p>
<ul>
<li>Decrease in the amount of drug uptake by cancer cells <ul>
<li>E.G. Methotrexate</li>
</ul>
</li>
<li>Increase in the amount of drug removed by cancer cells. (Transporters&#x3D;P-glycoprotein).<ul>
<li>E.G. Vinblastine ,doxorubicin, bleomycin ,etapsoid….</li>
</ul>
</li>
<li>Decrease or alteration in target molecule sensitivity – this is caused by mutation in the molecule targeted by the drug<ul>
<li>E.G. Methotrexate,Mercaptopurine,doxorubicin</li>
</ul>
</li>
<li>Increase in DNA repair ability of the cell via an increased expression of DNA repairing enzymes.<ul>
<li>E.G. Alkylating agent</li>
</ul>
</li>
</ul>
<h4 id="Resistance-Mechanisms"><a href="#Resistance-Mechanisms" class="headerlink" title="Resistance Mechanisms"></a>Resistance Mechanisms</h4><p>Alterations that affect the <strong>mechanism of action</strong> of the drugs:</p>
<ol>
<li>increased DNA repair: crosslinking agents, bleorsycin</li>
<li>formation of trapping agents: crosslinking agents</li>
<li>changes in target proteins (esp. enzymes): drugs that prevent DNA synthesis, some natural products, signal transduction inhibitors, antibodies</li>
</ol>
<p>Alterations that affect drug concentrations <strong>inside the tumour cell</strong>:</p>
<ol>
<li>decreased activation of prodrugs: <strong>5-fluorouracil, cyclophosphamide, trinotecan</strong></li>
<li>increased inactivation: antimetabolites (esp. purine analogues)</li>
<li>decreased accumulation:<ol>
<li>decreased transport into the cell: folate analogues, <strong>mechlorethamine</strong> platins</li>
<li>increased export from the cell due upregulation of efflux transporters(esp <u>increased P-glycoprotein</u>) natural products(esp. anthracyclines, vinca alkaloids taxanes, epipodophyllotoxins)<ul>
<li>this is an important cause of <strong>multidrug resistance</strong></li>
</ul>
</li>
</ol>
</li>
</ol>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204921275.png" srcset="/img/loading.gif" lazyload alt="image-20210524204921275" style="zoom:100%;" />

<h4 id="The-P-Glycoprotein-Structure"><a href="#The-P-Glycoprotein-Structure" class="headerlink" title="The P-Glycoprotein Structure"></a>The P-Glycoprotein Structure</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210524204932275.png" srcset="/img/loading.gif" lazyload alt="image-20210524204932275" style="zoom:100%;" />
+ Encoded by ABCB1 gene

<h3 id="2-Toxicity-and-side-Effects-of-Antineoplastic-Agents"><a href="#2-Toxicity-and-side-Effects-of-Antineoplastic-Agents" class="headerlink" title="2. Toxicity and side Effects of Antineoplastic Agents"></a>2. Toxicity and side Effects of Antineoplastic Agents</h3><p>Normal cells in the body that tend to be injured the most due to chemotherapy are those which have a high growth fraction. Those are bone marrow, GI Tract ,hair follicles, reproductive organs .Leading to the followings:</p>
<ul>
<li>Alopecia (脱发) - hair loss</li>
<li>Myelosuppression  (骨髓功能抑制) - bone marrow loss</li>
<li>Emetic potential (呕吐): disruptive to cells in stomach which causes: Nausea&#x2F;vomiting</li>
<li>Low WBC count (低白细胞数目) - low immunity</li>
</ul>
<h3 id="3-Treatment-induced-tumor"><a href="#3-Treatment-induced-tumor" class="headerlink" title="3. Treatment-induced tumor"></a>3. Treatment-induced tumor</h3><p>Many anticancer drugs are mutagens and can cause the rise of neoplasm ten or more years after the original cancer was cured</p>
<h1 id="三、Anti-Cancer-drugs-and-their-Pharmacology"><a href="#三、Anti-Cancer-drugs-and-their-Pharmacology" class="headerlink" title="三、Anti-Cancer drugs and their Pharmacology"></a>三、Anti-Cancer drugs and their Pharmacology</h1><h2 id="Why-term-chemtherapy"><a href="#Why-term-chemtherapy" class="headerlink" title="Why term chemtherapy"></a>Why term chemtherapy</h2><p>Like infective disease</p>
<ul>
<li>Some malignant cells can be cultured </li>
<li>Some malignancies can be transmitted by innoculation</li>
</ul>
<p>Cancer chemotherapy not as successful as antimicrobial chemotherapy</p>
<p>Metabolism in parasite differs qualitatively from host cells, while metabolism in cancer cells differ only quantitatively from normal host cells </p>
<ul>
<li>Hence target selectivity is more difficult in cancer </li>
<li>cancer there is no substantial immune response </li>
<li>Diagnostic complexity: delay in institution of treatment</li>
</ul>
<p>Cancer cells differ from normal cells by</p>
<ul>
<li>Uncontrolled proliferation</li>
<li>De-differentiation loss of function</li>
<li>Invasiveness</li>
<li>Metastasis</li>
</ul>
<h2 id="Cell-Cycle-and-Cancer"><a href="#Cell-Cycle-and-Cancer" class="headerlink" title="Cell Cycle and Cancer"></a>Cell Cycle and Cancer</h2><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135050395.png" srcset="/img/loading.gif" lazyload alt="image-20210525135050395" style="zoom:100%;" />
The cell cycle and Cancer: both Normal and Cancer cells must traverse before and after cell division.

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135059029.png" srcset="/img/loading.gif" lazyload alt="image-20210525135059029" style="zoom:100%;" />

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135104615.png" srcset="/img/loading.gif" lazyload alt="image-20210525135104615" style="zoom:100%;" />

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525135120792.png" srcset="/img/loading.gif" lazyload alt="image-20210525135120792" style="zoom: 67%;" />

<h2 id="Classification-of-Anti-Cancer-Drugs"><a href="#Classification-of-Anti-Cancer-Drugs" class="headerlink" title="Classification of Anti-Cancer Drugs"></a>Classification of Anti-Cancer Drugs</h2><h3 id="1-Overall-classifications"><a href="#1-Overall-classifications" class="headerlink" title="1. Overall classifications"></a>1. Overall classifications</h3><table>
<thead>
<tr>
<th>Category</th>
<th>Drugs</th>
</tr>
</thead>
<tbody><tr>
<td>Alkylating Agents</td>
<td>Cyclophosphamide, Nitrosourea, Platinum analogs: Cisplatin, Carboplatin</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>Cytarabine, Fludarabine, Methotrexate</td>
</tr>
<tr>
<td>Plant alkaloids</td>
<td>Camptothecins, Etoposide, Paclitaxel, Vinblastine</td>
</tr>
<tr>
<td>Antitumor antibiotics</td>
<td>Bleomycin, Doxorubicin, Mitomycin</td>
</tr>
<tr>
<td>Hormonal Agents</td>
<td>Flutamide, Leuprolide,Tamoxifen</td>
</tr>
<tr>
<td>Differential Inducer</td>
<td>Arsenic trioxide, Retinoic acid derivatives</td>
</tr>
<tr>
<td>Gene targeted drugs</td>
<td>Cetuximab, Dasatinib, Gefitinib, Imatinib</td>
</tr>
<tr>
<td>Immunomodulators</td>
<td>Including cytokines and growth factors</td>
</tr>
<tr>
<td>Antiangiogenesis drugs</td>
<td>sorafenib, sunitinib, pazopanib</td>
</tr>
</tbody></table>
<h3 id="2-Polyfunctional-Alkylating-Agents"><a href="#2-Polyfunctional-Alkylating-Agents" class="headerlink" title="2. Polyfunctional Alkylating Agents"></a>2. Polyfunctional Alkylating Agents</h3><h4 id="Introduction-and-classification"><a href="#Introduction-and-classification" class="headerlink" title="Introduction and classification"></a>Introduction and classification</h4><p><strong>Alkylation</strong> is the transfer of an alkyl group from one molecule to another.</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525141253371.png" srcset="/img/loading.gif" lazyload alt="image-20210525141253371" style="zoom:100%;" />
An **alkylating antineoplastic agent** is an alkylating agent used in cancer treatment that attaches an alkyl group (CnH2n+1) to DNA, especially on the guanine base of DNA, at the number 7 nitrogen atom of the purine ring

<p><strong>Alkylating agents classification</strong>:</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525141330998.png" srcset="/img/loading.gif" lazyload alt="image-20210525141330998" style="zoom:100%;" />
| Categories        | Drugs                                                     |
| ----------------- | --------------------------------------------------------- |
| Nitrogen mustards | Mechlorethamine,Melphalan,Cyclophosphamide,Chlorambu cil  |
| Ethyleneimines    | Thiotepa                                                  |
| Nitrosoureas      | Carmustine,Lomustine                                      |
| Alkylsulfonates   | Busulphan                                                 |
| Platinum          | Coordination complexes: Cisplatin,Carboplatin,Oxaliplatin |

<h4 id="Structures-of-alkylating-agents"><a href="#Structures-of-alkylating-agents" class="headerlink" title="Structures of alkylating agents"></a>Structures of alkylating agents</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142139737.png" srcset="/img/loading.gif" lazyload alt="image-20210525142139737" style="zoom:100%;" />
#### Alkylation: Mechanisms

<p>Attach an alkyl group to various cellular constituents:</p>
<ul>
<li>DNA—the major attacking subjects: Guanine (N7) , Adenine (N1, N3), Cytosine (N3) and Guanine (O6).</li>
<li>Proteins in various groups, including:<ul>
<li>Sulfhydryl</li>
<li>Hydrocyl</li>
<li>Phosphate group</li>
<li>Amino</li>
<li>Carboxyl</li>
</ul>
</li>
<li>Carbomoylation of lysine residues by nitrosourea through formation of isocyanates.</li>
<li>Non cell cycle specific, but preferentially attack cells at late G1 and S phases, thus blocking cells at G2</li>
</ul>
<h4 id="Mechanisms-of-Alkylation-of-DNA-Guanine"><a href="#Mechanisms-of-Alkylation-of-DNA-Guanine" class="headerlink" title="Mechanisms of Alkylation of DNA Guanine"></a>Mechanisms of Alkylation of DNA Guanine</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142258974.png" srcset="/img/loading.gif" lazyload alt="image-20210525142258974" style="zoom:100%;" />
#### Mechanisms of Alkylating Action in DNA

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142315443.png" srcset="/img/loading.gif" lazyload alt="image-20210525142315443" style="zoom: 67%;" />
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525142322670.png" srcset="/img/loading.gif" lazyload alt="image-20210525142322670" style="zoom: 67%;" />



<h4 id="Resistance-to-Alkylating-agents"><a href="#Resistance-to-Alkylating-agents" class="headerlink" title="Resistance to Alkylating agents"></a>Resistance to Alkylating agents</h4><p>Acquired resistance</p>
<ul>
<li>Increased capability to repair DNA lesions</li>
<li>Decreased transport of the alkylating drug into the cell</li>
<li>Increased production of glutathione and glutathione-associated proteins, which are needed to conjugate the alkylating agent, or increased glutathione S-transferase activity, which catalyzes the conjugation.</li>
</ul>
<h3 id="3-Platinum-Analogs"><a href="#3-Platinum-Analogs" class="headerlink" title="3. Platinum Analogs"></a>3. Platinum Analogs</h3><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143532638.png" srcset="/img/loading.gif" lazyload alt="image-20210525143532638" style="zoom:100%;" />
1. Inorganic metal complex
2. They kill tumor cells in all stages of the cell cycle
3. Bind DNA through the formation of intrastrand and interstrand cross-links
4. Leading to inhibition of DNA synthesis and function.
5. N7 Guanine, N3 Adenine,O6 cytosine can also occur.
6. Nephrotoxicity acould be attenuated by i.v. saline infusion.
7. Used for NSCLC, GU, gastric, head and neck, ovarian and bladder cancers
8. Synergistic with other anticancer agents :Alkylating agents, taxanes

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143608863.png" srcset="/img/loading.gif" lazyload alt="image-20210525143608863" style="zoom: 67%;" />

<h3 id="4-Antimetabolic-Agents"><a href="#4-Antimetabolic-Agents" class="headerlink" title="4. Antimetabolic Agents"></a>4. Antimetabolic Agents</h3><ol>
<li>Structural analogues: Neoplastic cells’ metabolic differences – increased susceptibility to actions of antimetabolites.</li>
<li>Most antimetabolites interfere with nucleic acid synthesis or nucleotide synthesis.</li>
<li><strong>Folic acid</strong> antagonist: methotrexate, pemetrexed</li>
<li><strong>Purine</strong> Antagonists: 6-Thiopurines, Fludarabine,</li>
<li><strong>Pyrimidine</strong> Antagonists: 5-Fluorouracil, Cytarabine, gemcitabine</li>
<li>DNA synthesis (S phase–specific)</li>
</ol>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143659938.png" srcset="/img/loading.gif" lazyload alt="image-20210525143659938" style="zoom:100%;" />

<h4 id="Methotrexate"><a href="#Methotrexate" class="headerlink" title="Methotrexate"></a>Methotrexate</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143741516.png" srcset="/img/loading.gif" lazyload alt="image-20210525143741516" style="zoom:100%;" />
**Method of action:** 

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143752339.png" srcset="/img/loading.gif" lazyload alt="image-20210525143752339" style="zoom:100%;" />
1. binds with high affinity to the active catalytic site of DHFR.
2. interfering with the synthesis of tetrahydrofolate (THF)
3. THF for de novo synthesis of thymidylate, purine nucleotides, and the amino acids serine and methionine.
4. DNA, RNA, and key cellular proteins

<h4 id="5-Fluorouracil"><a href="#5-Fluorouracil" class="headerlink" title="5-Fluorouracil"></a>5-Fluorouracil</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525143843235.png" srcset="/img/loading.gif" lazyload alt="image-20210525143843235" style="zoom:67%;" />

<ol>
<li>Uridine derivatives</li>
<li>One derivative, 5-fluoro-2’-deoxyuridine 5’-phosphate (FdUMP),inhibits thymidylate synthase and its cofactor,a tetrahydrofolate derivative,resulting in inhibition of thymidine nucleotide synthesis.</li>
<li>Another derivative, 5-fluorouridine triphosphate is incorporated into RNA, interfering with RNA function.</li>
<li>Cytotoxicity: effects on both RNA and DNA</li>
</ol>
<h4 id="Cytarabine-ara-C"><a href="#Cytarabine-ara-C" class="headerlink" title="Cytarabine (ara-C)"></a>Cytarabine (ara-C)</h4><p>IV administration</p>
<p>S phase specificity: highly schedule-dependent</p>
<p>Clinical Use: almost exclusively for acute myelogenous leukemia</p>
<p>MOA</p>
<ul>
<li>S phase-specific antimetabolite</li>
<li>Biotransformed to active forms: ara-CTP, competitive inhibitor of DNA polymerase.</li>
<li>Blocks DNA synthesis; no effect on RNA or protein synthesis cytarabine incorporated into RNA and DNA – interfering with chain elongation</li>
</ul>
<p>AE (side effect):</p>
<ul>
<li>nausea, alopecia stomatitis , severe myelosuppression</li>
</ul>
<h3 id="5-Natural-Products-for-Cancer-Chemotherapy-Plant-Alkaloids"><a href="#5-Natural-Products-for-Cancer-Chemotherapy-Plant-Alkaloids" class="headerlink" title="5. Natural Products for Cancer Chemotherapy: Plant Alkaloids"></a>5. Natural Products for Cancer Chemotherapy: Plant Alkaloids</h3><p>function can be totally different</p>
<p>Example: Vincristine, vinblastine, Etoptosides, Camptothecin, Taxanes: Paclitaxel, Doxetaxel</p>
<p><strong>Alkaloid</strong>, any of a class of naturally occurring organic nitrogen-containing bases</p>
<h4 id="vinblastine-and-vincristine"><a href="#vinblastine-and-vincristine" class="headerlink" title="vinblastine and vincristine"></a>vinblastine and vincristine</h4><p><strong>Resource</strong>: plant products, from periwinkle plant—vinca rosea</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164029948.png" srcset="/img/loading.gif" lazyload alt="image-20210525164029948" style="zoom:100%;" />

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164043950.png" srcset="/img/loading.gif" lazyload alt="image-20210525164043950" style="zoom:67%;" />

<p>Function:</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164053841.png" srcset="/img/loading.gif" lazyload alt="image-20210525164053841" style="zoom:100%;" />
+ **inhibition of tubulin polymerization**, which disrupts assembly of microtubules, an important part of the cytoskeleton and the mitotic spindle. This inhibitory effect results in mitotic arrest in metaphase, bringing cell division to a halt, which then leads to cell death.

<p><strong>Applications</strong>:</p>
<ul>
<li>Vinblastine<ul>
<li>Cure for: <ul>
<li>Hodgkin’s lymphoma </li>
<li>Non-Hodgkin’s lymphoma </li>
<li>Breast cancer </li>
<li>Germ cell cancer</li>
</ul>
</li>
<li>AE: <ul>
<li>Nausea and vomitting</li>
<li>bone marrow suppression</li>
<li>alopecia</li>
</ul>
</li>
</ul>
</li>
</ul>
<h4 id="Camptothecins-Topotecan-Irinotecan"><a href="#Camptothecins-Topotecan-Irinotecan" class="headerlink" title="Camptothecins: Topotecan, Irinotecan"></a>Camptothecins: Topotecan, Irinotecan</h4><p><strong>Resource</strong>: camptotheca acuminata <strong>tree</strong></p>
<p><strong>MOA</strong>: inhibition of topoisomerase I, the key enzyme responsible for cutting and religating single DNA strands –DNA damage</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164345230.png" srcset="/img/loading.gif" lazyload alt="image-20210525164345230" style="zoom:100%;" />

<p><strong>Indications（适应症）</strong>:</p>
<ul>
<li><strong>Topotecan (拓扑替康)</strong>–2nd line therapy for: Advanced ovarian cancer, small cell lung cancer</li>
<li><strong>Irinotecan (伊立替康；依立替康；抗癌妥)</strong>—metastatic colorectal cancer as a monotherapy who has failed to 5-FU. Or used as 1st line in combination with 5FU and leucovorin</li>
</ul>
<p><strong>AE</strong>: myelosuppression and diarrhea</p>
<h4 id="Taxanes-Taxol"><a href="#Taxanes-Taxol" class="headerlink" title="Taxanes, Taxol"></a>Taxanes, Taxol</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164941329.png" srcset="/img/loading.gif" lazyload alt="image-20210525164941329" style="zoom:100%;" />
+ Paclitaxel

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525164949067.png" srcset="/img/loading.gif" lazyload alt="image-20210525164949067" style="zoom:100%;" />
#### The PK&PD of Taxol

<p>Administration</p>
<ul>
<li>Intravenous(135～350 mg&#x2F;m2, 3h or 24h)</li>
<li>Intraperitoneal(60～65 mg&#x2F;m2, every week)</li>
<li>Lipid-soluble</li>
<li>MW&#x3D;853.91</li>
</ul>
<p>Distribution</p>
<ul>
<li>Liver, lung, pancreas, salivary glands, stomach, heart, muscle, kidney, etc.</li>
<li>Couldn’t pass the blood brain barrier</li>
</ul>
<p>Elimination</p>
<ul>
<li>Cytochrome P450 occur(CYP2C&amp;CYP3A)</li>
<li>Form 6α-hydroxylated paclitaxel</li>
</ul>
<p>Half-Life Elimination</p>
<p>Children: 4.6 to 17 hours (varies with dose and infusion duration)</p>
<p>Adults: </p>
<ul>
<li>3-hour infusion: Mean (terminal): ~13 to 20 hours</li>
<li>24-hour infusion: Mean (terminal): ~16 to 53 hours</li>
</ul>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170126311.png" srcset="/img/loading.gif" lazyload alt="image-20210525170126311" style="zoom:100%;" />
#### Mechanism&Usage

<p>Paclitaxel is one of several cytoskeletal drugs that target tubulin. Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome segregation, and cell division. </p>
<p>Unlike other tubulin-targeting drugs, such as colchicine, that inhibit microtubule assembly, <u>paclitaxel stabilizes the microtubule polymer and protects it from disassembly.</u></p>
<p><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170148030.png" srcset="/img/loading.gif" lazyload alt="image-20210525170148030" style="zoom:100%;" /><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525170709521.png" srcset="/img/loading.gif" lazyload alt="image-20210525170709521" style="zoom:100%;" /><br>Usage</p>
<ul>
<li>Anal cancer, advanced</li>
<li>Bladder cancer, advanced or metastatic</li>
<li>Breast cancer, adjuvant treatment</li>
<li>Breast cancer, metastatic or relapsed</li>
<li>Cervical cancer, advanced</li>
<li>Endometrial cancer, advanced or recurrent</li>
<li>Esophageal cancer, metastatic or unresectable locally advanced</li>
<li>Esophageal&#x2F;esophagogastric cancer, preoperative chemoradiation</li>
<li>Gastric cancer, metastatic or unresectable locally advanced</li>
<li>Head and neck cancers, advanced</li>
<li>Kaposi sarcoma, AIDS related</li>
<li>Melanoma, advanced or metastatic</li>
<li>Non-small cell lung cancer</li>
<li>Ovarian cancer, advanced</li>
<li>Penile cancer, metastatic</li>
<li>Small cell lung cancer, relapsed&#x2F;refractory</li>
<li>Soft tissue sarcoma (angiosarcoma), advanced&#x2F;unresectable</li>
<li>Testicular germ cell tumors, relapsed&#x2F;refractory</li>
<li>Thymoma&#x2F;thymic carcinoma, advanced</li>
<li>Thyroid cancer, anaplastic</li>
<li>Unknown primary adenocarcinoma</li>
</ul>
<h4 id="Side-effects"><a href="#Side-effects" class="headerlink" title="Side effects"></a>Side effects</h4><p>Anaphylaxis</p>
<p>Alopecia, headache, edema, weakness, etc</p>
<h3 id="9-Natural-Products-for-Cancer-Chemotherapy-Anti-tumor-antibiotics"><a href="#9-Natural-Products-for-Cancer-Chemotherapy-Anti-tumor-antibiotics" class="headerlink" title="9. Natural Products for Cancer Chemotherapy: Anti-tumor antibiotics"></a>9. Natural Products for Cancer Chemotherapy: Anti-tumor antibiotics</h3><p>From microbes: <em>Streptomyces</em> (链霉菌属)</p>
<p>Example:</p>
<ul>
<li>Anthracyclines: doxorubicin, daunorubicin</li>
<li>Mitoxantrone, Dactinomycin</li>
<li>Mitomycin</li>
<li>Bleomycin</li>
</ul>
<p><strong>MOA:</strong></p>
<p>Bind to DNA through intercalation between specific bases and block the synthesis of RNA, DNA, or both</p>
<p>Cause DNA strand scission; and interfere with cell replication</p>
<p>Include the <strong>anthracyclines</strong>, bleomycin, and <strong>mitomycin</strong></p>
<h4 id="Anthracyclines"><a href="#Anthracyclines" class="headerlink" title="Anthracyclines"></a>Anthracyclines</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525171044816.png" srcset="/img/loading.gif" lazyload alt="image-20210525171044816" style="zoom:100%;" />

<ol>
<li>Inhibition of topoisomerase II; </li>
<li>high-affinity <strong>binding to DNA through intercalation</strong>, with consequent blockade of the synthesis of DNA and RNA, and DNA strand scission; </li>
<li>generation of semiquinone free radicals and oxygen free radicals through an iron-dependent, enzyme-mediated reductive process; </li>
<li>binding to cellular membranes to alter fluidity and ion transport</li>
</ol>
<p><strong>Indications</strong></p>
<ul>
<li><strong>Doxorubicin—Most used one</strong><ul>
<li>Solid cancers : breast, endometrium, ovary, testicle, thyroid, stomach, bladder, liver, and lung</li>
<li>Soft tissue sarcomas</li>
<li>Childhood cancers, including neuroblastoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma</li>
<li>Hematologic malignancies<ul>
<li>acute lymphoblastic leukemia</li>
<li>multiple myeloma</li>
<li>Hodgkin’s and non-Hodgkin’s lymphomas</li>
</ul>
</li>
</ul>
</li>
<li>Daunorubicin—First identified one<ul>
<li>Acute myeloid leukemia.</li>
<li>Limited for solid tumors</li>
</ul>
</li>
</ul>
<h4 id="Mitomycin-C"><a href="#Mitomycin-C" class="headerlink" title="Mitomycin C"></a>Mitomycin C</h4><p><strong>MOA</strong></p>
<ul>
<li>Metabolic activation through an enzyme-mediated reduction;</li>
<li>An alkylating agent that cross-links DNA<ul>
<li>Active for all cell cycles.</li>
</ul>
</li>
</ul>
<p><strong>Used in combination with radiotherapy</strong>:</p>
<ul>
<li>Hypoxic tumor stem cells , the most sensitive one to MMC. </li>
<li>Squamous cell cancer of the anus </li>
<li>Squamous cell carcinoma of the cervix </li>
<li>Breast, gastric, and pancreatic cancer. </li>
<li>Superficial bladder cancer–intravesical treatment while no systemic toxicity</li>
</ul>
<h4 id="Bleomycin"><a href="#Bleomycin" class="headerlink" title="Bleomycin"></a>Bleomycin</h4><p>Features:</p>
<ul>
<li>Glycopeptide antibiotics isolated from Streptomyces verticillus. </li>
<li>Contains a DNA-binding region and an iron-binding domain</li>
</ul>
<p><strong>MOA:</strong></p>
<ul>
<li>Binding to DNA, which results in <u>single-stranded and double-stranded breaks</u> following free radical formation </li>
<li>Inhibition of DNA biosynthesis. </li>
<li>DNA fragmentation is due to oxidation of a DNA-bleomycin-Fe(II) complex , which leads to chromosomal aberrations</li>
</ul>
<p>Bleomycin is a cell cycle-specific drug that causes accumulation of cells in the <strong>G2 phase</strong> of the cell cycle</p>
<p><strong>Indications:</strong></p>
<ul>
<li>Hodgkin’s and non-Hodgkin’s lymphomas</li>
<li>Germ cell tumor, head and neck cancer, and squamous cell cancer of the skin, cervix, and vulva.</li>
</ul>
<h4 id="Hormonal-Agents"><a href="#Hormonal-Agents" class="headerlink" title="Hormonal Agents"></a>Hormonal Agents</h4><p><strong>Estrogen inhibitors</strong>: <strong>Tamoxifen</strong>-antiestrogen, for breast cancer, endometrial cancer</p>
<p><strong>Androgen</strong> inhibitor:</p>
<ul>
<li>Flutamide—binds to Androgen receptor; Prostate cancer </li>
<li>Bicalutamide</li>
</ul>
<h5 id="1-Tamoxifen"><a href="#1-Tamoxifen" class="headerlink" title="(1) Tamoxifen"></a>(1) Tamoxifen</h5><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172442824.png" srcset="/img/loading.gif" lazyload alt="image-20210525172442824" style="zoom:50%;" />



<ol>
<li>Binds to the ER of the breast tumor</li>
<li>Competitive inhibitor of the ER</li>
<li>Suppresses IGF1 and TGF-β</li>
<li>Therapies for: breast cancer, earlier or metastatic</li>
<li>Prevention for: Breast cancer</li>
</ol>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172655578.png" srcset="/img/loading.gif" lazyload alt="image-20210525172655578" style="zoom:100%;" />
### 10. Molecularly Targeted Anti-cancer Drugs

<h4 id="PI3K-AKT-Signaling"><a href="#PI3K-AKT-Signaling" class="headerlink" title="PI3K-AKT Signaling"></a>PI3K-AKT Signaling</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172934902.png" srcset="/img/loading.gif" lazyload alt="image-20210525172934902" style="zoom: 50%;" />

<p>PI3K Pathway Inhibitors：</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525172950715.png" srcset="/img/loading.gif" lazyload alt="image-20210525172950715" style="zoom: 50%;" />

<h4 id="Genetic-Aberrations"><a href="#Genetic-Aberrations" class="headerlink" title="Genetic Aberrations"></a>Genetic Aberrations</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173019126.png" srcset="/img/loading.gif" lazyload alt="image-20210525173019126" style="zoom:100%;" />
##### (1) Imatinib (Gleevec)

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173032440.png" srcset="/img/loading.gif" lazyload alt="image-20210525173032440" style="zoom:100%;" />
**MOA**: inhibition of the tyrosine kinase Bcl/ABL, prevents its phosphorylation by ATP.

<p>Indications:</p>
<ul>
<li>Approved for Ph+ chronic phase of CML (chronic myeloid leukemia),balst crisis that ahs progressed on prior interferon α</li>
<li>Gastrointestinal stromal tumors expressing the c-kit tyrosine kinase</li>
</ul>
<h5 id="2-Dasatinib-Sprycel"><a href="#2-Dasatinib-Sprycel" class="headerlink" title="(2) Dasatinib (Sprycel)"></a>(2) Dasatinib (Sprycel)</h5><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173303528.png" srcset="/img/loading.gif" lazyload alt="image-20210525173303528" style="zoom: 67%;" />

<ul>
<li>Crystal structure of Abl kinase domain (blue) in complex with dasatinib (red).</li>
</ul>
<p>The main targets: BCR&#x2F;ABL, Src, c-Kit, ephrin receptors, and several other tyrosine kinases, but not erbB kinases such as EGFR or Her2</p>
<ul>
<li>Oral inhibitor</li>
<li>Indications: CML , ALL with Ph+</li>
<li>AE: Neutropenia, myelosuppression</li>
</ul>
<h5 id="3-Gefitinib-Iresa-and-Erlotinib-Tarcera"><a href="#3-Gefitinib-Iresa-and-Erlotinib-Tarcera" class="headerlink" title="(3) Gefitinib (Iresa) and Erlotinib (Tarcera)"></a>(3) Gefitinib (Iresa) and Erlotinib (Tarcera)</h5><ol>
<li>Gefitinib is an <strong>EGFR (epidermal growth factor receptor) inhibitor</strong>, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR, such as breast and lung cancers.</li>
<li>Is a drug used for certain <strong>breast, lung</strong> and other cancers</li>
<li>It is <u>not a chemotherapeutic</u> in the traditional sense, since it does not cause the destruction of tumor cells. Instead, gefitnib interferes with the growth and spread of new cancer cells. <u>Anti-tumor but not cytotoxic.</u></li>
<li>Patients who don’t smoke with a bronchoaleolar subtype have a good resposiveness.</li>
<li>Tarcera approved for advanced pancreatic cancer in combination with gemcitabine.</li>
<li>AE: diarrhea, acneifrom skin rash</li>
</ol>
<h5 id="4-Cetuximab"><a href="#4-Cetuximab" class="headerlink" title="(4) Cetuximab"></a>(4) Cetuximab</h5><p><strong>MOA</strong>:</p>
<ul>
<li>Epidermal growth factor receptor inhibitor. </li>
<li>Chimeric monoclonal antibody directly against the extracellular domain of EGFR</li>
</ul>
<p><strong>Indications:</strong></p>
<ul>
<li>For metastetic colorectal cancer in combination with irinotecan or oxaliplatin. </li>
<li>For locally advanced head and neck cancer in combination with radiation therapy.</li>
</ul>
<h4 id="Proteasome-and-protein-degradation"><a href="#Proteasome-and-protein-degradation" class="headerlink" title="Proteasome and protein degradation"></a>Proteasome and protein degradation</h4><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525173917874.png" srcset="/img/loading.gif" lazyload alt="image-20210525173917874" style="zoom:100%;" />
##### (1) Bortezomib (Velcade)

<ul>
<li>1st line for mutliple myeloma</li>
<li>2nd line for mantle cell lymphoma</li>
</ul>
<p>the first and only FDA approved anti-cancer agent among proteasome inhibitors</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525174006082.png" srcset="/img/loading.gif" lazyload alt="image-20210525174006082" style="zoom:67%;" />

<ul>
<li>highly selective </li>
<li>Reversible </li>
<li>26S proteasome complex </li>
<li>Most effective on Myeloma </li>
<li>Effects the bone metabolism in MM </li>
<li>Sensitizes them toward conventional chemotherapy </li>
<li>Prolongs patients’ survival by overcoming resistance to conventional drugs</li>
</ul>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525174038754.png" srcset="/img/loading.gif" lazyload alt="image-20210525174038754" style="zoom:67%;" />

<h4 id="Differentiation-Inducers"><a href="#Differentiation-Inducers" class="headerlink" title="Differentiation Inducers"></a>Differentiation Inducers</h4><ol>
<li>Retinoic acid derivatives </li>
<li>Arsenic trioxide</li>
</ol>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175114183.png" srcset="/img/loading.gif" lazyload alt="image-20210525175114183" style="zoom:100%;" />

<p>Specific for APL, acute promyelocytic leukemia by induction of terminal <strong>differentiation</strong> thus losing its ability to proliferate</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175240334.png" srcset="/img/loading.gif" lazyload alt="image-20210525175240334" style="zoom:100%;" />
#### Arenic Trioxide (As2O3)

<p>Indications: 2nd line for APL with t(15:17) translocation, refractory to ATRA or anthracyclines.</p>
<p><strong>MOA</strong>: </p>
<ul>
<li>degradation of the chimeric protein PML&#x2F;RARa</li>
<li>mitochondria-dependent cell apoptosis</li>
</ul>
<p>Administration: intravenous.</p>
<p>AE: fatigue, electrocardiographic changes (QT prolongation), arrhythmias.</p>
<h2 id="Summary-of-Mechanisms-of-Action"><a href="#Summary-of-Mechanisms-of-Action" class="headerlink" title="Summary of Mechanisms of Action"></a>Summary of Mechanisms of Action</h2><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525152058913.png" srcset="/img/loading.gif" lazyload alt="image-20210525152058913" style="zoom:100%;" />


<h1 id="四、Chemotherapy-Pros-and-Cons"><a href="#四、Chemotherapy-Pros-and-Cons" class="headerlink" title="四、Chemotherapy: Pros and Cons"></a>四、Chemotherapy: Pros and Cons</h1><p><strong>A broad spectrum</strong> : almost all kinds of cancers from all organs, including Brain cancer, blood cancers, breast cancer, colon cancer, gastric cancer, lung cancer cancer, prostate cancer….</p>
<p>Kill cancer cells that <u>rapidly grow,</u> or specific genetic presented cancers</p>
<p>More effective when used in <strong>combination</strong> with other drugs or other methods, such as surgery or radiotherapy.</p>
<p><strong>No anticancer drugs</strong> are perfect that kill cancer cells only.</p>
<p>Most adverse effects are:</p>
<ol>
<li>Myelosuppression—anemia, hemorrhage, prone to infection</li>
<li>Somatitis</li>
<li>Alopecia</li>
<li>Gastrointestinal effects.</li>
</ol>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175504627.png" srcset="/img/loading.gif" lazyload alt="image-20210525175504627" style="zoom:100%;" />
+ Therapeutic targeting of the hallmarks of cancer.

<h1 id="五、Tumor-Immuno-Therapy"><a href="#五、Tumor-Immuno-Therapy" class="headerlink" title="五、Tumor-Immuno Therapy"></a>五、Tumor-Immuno Therapy</h1><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175644835.png" srcset="/img/loading.gif" lazyload alt="image-20210525175644835" style="zoom:100%;" />
## Immune system and cancer

<p>The immune system serves as one of the primary defenses against cancer. <u>When normal tissue becomes a tumor or cancerous tissue, new antigens develop on their surface</u>. </p>
<p>These antigens send a signal to immune cells such as the T lymphocytes and macrophages, which in turn <u>directly kill</u> the tumor cells or release substances like <strong>cytokines</strong> that may bring about tumor cell death.</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175715808.png" srcset="/img/loading.gif" lazyload alt="image-20210525175715808" style="zoom:100%;" />
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175724146.png" srcset="/img/loading.gif" lazyload alt="image-20210525175724146" style="zoom:100%;" />
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175734353.png" srcset="/img/loading.gif" lazyload alt="image-20210525175734353" style="zoom:100%;" />
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175742320.png" srcset="/img/loading.gif" lazyload alt="image-20210525175742320" style="zoom:100%;" />
## Abridged history of cancer immunotherapy: Disappointing until recently

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525175753074.png" srcset="/img/loading.gif" lazyload alt="image-20210525175753074" style="zoom:100%;" />
+ 2011: Ipiliumumab shows overall survival benefit in melanoma
+ 2012-2014: PD1 and PD-L1 blockade has benefit in melanoma and lung
+ cancer 2011-2014: CAR-modified T cells show durable remissions in leukemia

<h2 id="Monoclonal-Antibodies"><a href="#Monoclonal-Antibodies" class="headerlink" title="Monoclonal Antibodies"></a>Monoclonal Antibodies</h2><p>Monoclonal antibodies are proteins produced in the laboratory from a single clone of a B−cell, the type of cells of the immune system that make antibodies. When used as a treatment for cancer, there are three general strategies with monoclonal antibodies:</p>
<ul>
<li>One uses the ability of the antibodies to <u>bind to the cancer cells having the tumor antigens on their surface.</u> The immune system will see the cancer cells marked with bound antibodies as foreign and destroy them</li>
<li>A second strategy is to use the antibodies to <u>block the binding of cytokines or other proteins that are needed by the cancerous cells to maintain their uncontrolled growth</u>. Monoclonal antibodies designed to work like this bind to the cytokine receptors that are on the tumor cell surface.</li>
<li>A <u>final</u> strategy involves <u>special antibodies that are linked (conjugated) to a substance that is deadly to the cancer cells</u>. E.G. radioactive isotopes, have been successfully conjugated to antibodies. The antibodies are then used to specifically destroy he tumor cells with the radioactivity or toxic substance</li>
</ul>
<p><strong>Trastuzumab</strong> (曲妥珠单抗)</p>
<ul>
<li>Trastuzumab is a humanized monoclonal antibody produced by recombinant DNA technology that binds specifically to the <u>human epidermal growth factor receptor</u> 2 protein (also known as HER2) that is found on the cell surface of some cancer tumors, most notably breast cancer(25−30% of breast malignancies) and also targets it for destruction by the natural killer cells of immune system.</li>
</ul>
<h2 id="Biological-response-modifiers"><a href="#Biological-response-modifiers" class="headerlink" title="Biological response modifiers"></a>Biological response modifiers</h2><p>Researchers have been working on <u>stimulating the immune cells</u> during cancer with substances broadly classified as biological response modifiers. <strong>Cytokines</strong> are one such substance. These are proteins that are predominantly released by immune cells upon activation or stimulation.</p>
<p><strong>Aldesleukin</strong></p>
<ul>
<li>Aldesleukin is interleukin, that is used to treat metastasis renal cell carcinoma (a form of kidney cancer) and metastasis melanoma. Aldesleukin is also known as interleukin−2, IL−2</li>
</ul>
<p><strong>Interferons</strong></p>
<ul>
<li>small, natural cytokines produced by leucocytes ,T−lymphocytes, and fibroblasts <u>to activate tumor−specific cytotoxic T−lymphocytes</u>. Thus, tumor cells would be destroyed based on immunotherapy</li>
<li>used to treat cancers such as hairy cell leukemia, malignant melanoma, and Kaposi’s sarcoma (an AIDS−related cancer) as well as many other cancers</li>
</ul>
<h2 id="Immune-therapy-can-overcome-tolerance"><a href="#Immune-therapy-can-overcome-tolerance" class="headerlink" title="Immune therapy can overcome tolerance"></a>Immune therapy can overcome tolerance</h2><p>Hallmark of cancer: induction of immune tolerance</p>
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184614504.png" srcset="/img/loading.gif" lazyload alt="image-20210525184614504" style="zoom:100%;" />
### 1. CAR T cells: personalized “serial killer” cells

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184705780.png" srcset="/img/loading.gif" lazyload alt="image-20210525184705780" style="zoom:50%;" />

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184756462.png" srcset="/img/loading.gif" lazyload alt="image-20210525184756462" style="zoom:67%;" />

<p>Gene transfer technology is used to stably express CARs on T cells, conferring novel antigen specificity</p>
<p>CART19 therapy takes advantage of the cytotoxic potential of T cells thereby killing tumor cells in an antigen-dependent manner</p>
<p>Persistent CART19 cells consist of both effector (cytotoxic) and central memory T cells</p>
<p>T cells are non-cross resistant to chemotherapy</p>
<p>Responses are cytolytic: no swelling!</p>
<h3 id="2-Using-Synthetic-Biology-to-Overcome-Tolerance-Creation-of-Bi-specific-CAR-T-cells"><a href="#2-Using-Synthetic-Biology-to-Overcome-Tolerance-Creation-of-Bi-specific-CAR-T-cells" class="headerlink" title="2. Using Synthetic Biology to Overcome Tolerance Creation of Bi-specific CAR T cells"></a>2. Using Synthetic Biology to Overcome Tolerance Creation of Bi-specific CAR T cells</h3><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184908253.png" srcset="/img/loading.gif" lazyload alt="image-20210525184908253" style="zoom:100%;" />
+ Design of CAR T Cells

<h3 id="3-Adult-Chronic-Leukemia-Study-Overview"><a href="#3-Adult-Chronic-Leukemia-Study-Overview" class="headerlink" title="3. Adult Chronic Leukemia Study Overview"></a>3. Adult Chronic Leukemia Study Overview</h3><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525184957613.png" srcset="/img/loading.gif" lazyload alt="image-20210525184957613" style="zoom:100%;" />
Immune Checkpoint Blockade: Mechanism of Action

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185018602.png" srcset="/img/loading.gif" lazyload alt="image-20210525185018602" style="zoom: 25%;" />

<h3 id="4-A-Road-Map-of-Immunotherapy-Agents-in-the-Cancer-Immune-System-Interaction"><a href="#4-A-Road-Map-of-Immunotherapy-Agents-in-the-Cancer-Immune-System-Interaction" class="headerlink" title="4. A Road Map of Immunotherapy Agents in the Cancer-Immune System Interaction"></a>4. A Road Map of Immunotherapy Agents in the Cancer-Immune System Interaction</h3><img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185127839.png" srcset="/img/loading.gif" lazyload alt="image-20210525185127839" style="zoom:100%;" />
<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185145400.png" srcset="/img/loading.gif" lazyload alt="image-20210525185145400" style="zoom:100%;" />
### 5. Immunosuppression is a rate limiting step to effective antitumor immunity

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185258096.png" srcset="/img/loading.gif" lazyload alt="image-20210525185258096" style="zoom:100%;" />
### 6. Broad activity for anti-PD-L1/PD-1 in human cancer

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185414485.png" srcset="/img/loading.gif" lazyload alt="image-20210525185414485" style="zoom:100%;" />
### 7. Immune checkpoints: more than PD-1 and CTLA-4

<img src="https://hexo20200628-1259353497.cos.ap-guangzhou.myqcloud.com/Articles/Academic_Notes/Molecular%20Pharmacology/image-20210525185436414.png" srcset="/img/loading.gif" lazyload alt="image-20210525185436414" style="zoom:100%;" />
                
              </div>
            
            <hr/>
            <div>
              <div class="post-metas my-3">
  
    <div class="post-meta mr-3 d-flex align-items-center">
      <i class="iconfont icon-category"></i>
      

<span class="category-chains">
  
  
    
      <span class="category-chain">
        
  <a href="/categories/Academic-Notebook/" class="category-chain-item">Academic Notebook</a>
  
  
    <span>></span>
    
  <a href="/categories/Academic-Notebook/Molecular-Pharmacology/" class="category-chain-item">Molecular Pharmacology</a>
  
  

  

      </span>
    
  
</span>

    </div>
  
  
    <div class="post-meta">
      <i class="iconfont icon-tags"></i>
      
        <a href="/tags/Molecular-Pharmacology/" class="print-no-link">#Molecular Pharmacology</a>
      
    </div>
  
</div>


              
  

  <div class="license-box my-3">
    <div class="license-title">
      <div>L14 Cancer Pharmacology</div>
      <div>https://zhenyumi.github.io/posts/6c8073ce/</div>
    </div>
    <div class="license-meta">
      
        <div class="license-meta-item">
          <div>作者</div>
          <div>向海</div>
        </div>
      
      
        <div class="license-meta-item license-meta-date">
          <div>发布于</div>
          <div>2021年6月1日</div>
        </div>
      
      
      
        <div class="license-meta-item">
          <div>许可协议</div>
          <div>
            
              
              
                <a class="print-no-link" target="_blank" href="https://creativecommons.org/licenses/by/4.0/">
                  <span class="hint--top hint--rounded" aria-label="BY - 署名">
                    <i class="iconfont icon-cc-by"></i>
                  </span>
                </a>
              
            
          </div>
        </div>
      
    </div>
    <div class="license-icon iconfont"></div>
  </div>



              
                <div class="post-prevnext my-3">
                  <article class="post-prev col-6">
                    
                    
                      <a href="/posts/168f52a5/" title="L15 Antimicrobial Drugs">
                        <i class="iconfont icon-arrowleft"></i>
                        <span class="hidden-mobile">L15 Antimicrobial Drugs</span>
                        <span class="visible-mobile">上一篇</span>
                      </a>
                    
                  </article>
                  <article class="post-next col-6">
                    
                    
                      <a href="/posts/c0f88b48/" title="L12 Anesthetics (General and local)">
                        <span class="hidden-mobile">L12 Anesthetics (General and local)</span>
                        <span class="visible-mobile">下一篇</span>
                        <i class="iconfont icon-arrowright"></i>
                      </a>
                    
                  </article>
                </div>
              
            </div>

            
          </article>
        </div>
      </div>
    </div>

    <div class="side-col d-none d-lg-block col-lg-2">
      
  <aside class="sidebar" style="margin-left: -1rem">
    <div id="toc">
  <p class="toc-header">
    <i class="iconfont icon-list"></i>
    <span>目录</span>
  </p>
  <div class="toc-body" id="toc-body"></div>
</div>



  </aside>


    </div>
  </div>
</div>





  



  



  



  



  


  
  









    

    
      <a id="scroll-top-button" aria-label="TOP" href="#" role="button">
        <i class="iconfont icon-arrowup" aria-hidden="true"></i>
      </a>
    

    
      <div class="modal fade" id="modalSearch" tabindex="-1" role="dialog" aria-labelledby="ModalLabel"
     aria-hidden="true">
  <div class="modal-dialog modal-dialog-scrollable modal-lg" role="document">
    <div class="modal-content">
      <div class="modal-header text-center">
        <h4 class="modal-title w-100 font-weight-bold">搜索</h4>
        <button type="button" id="local-search-close" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body mx-3">
        <div class="md-form mb-5">
          <input type="text" id="local-search-input" class="form-control validate">
          <label data-error="x" data-success="v" for="local-search-input">关键词</label>
        </div>
        <div class="list-group" id="local-search-result"></div>
      </div>
    </div>
  </div>
</div>

    

    
  </main>

  <footer>
    <div class="footer-inner">
  
    <div class="footer-content">
       <a href="https://hexo.io" target="_blank" rel="nofollow noopener"><span>Hexo</span></a> <i class="iconfont icon-love"></i> <a href="https://github.com/fluid-dev/hexo-theme-fluid" target="_blank" rel="nofollow noopener"><span>Fluid</span></a> 
    </div>
  
  
  
</div>

  </footer>

  <!-- Scripts -->
  
  <script  src="https://lib.baomitu.com/nprogress/0.2.0/nprogress.min.js" ></script>
  <link  rel="stylesheet" href="https://lib.baomitu.com/nprogress/0.2.0/nprogress.min.css" />

  <script>
    NProgress.configure({"showSpinner":false,"trickleSpeed":100})
    NProgress.start()
    window.addEventListener('load', function() {
      NProgress.done();
    })
  </script>


<script  src="https://lib.baomitu.com/jquery/3.6.4/jquery.min.js" ></script>
<script  src="https://lib.baomitu.com/twitter-bootstrap/4.6.1/js/bootstrap.min.js" ></script>
<script  src="/js/events.js" ></script>
<script  src="/js/plugins.js" ></script>





  
    <script  src="/js/img-lazyload.js" ></script>
  




  
<script>
  Fluid.utils.createScript('https://lib.baomitu.com/tocbot/4.20.1/tocbot.min.js', function() {
    var toc = jQuery('#toc');
    if (toc.length === 0 || !window.tocbot) { return; }
    var boardCtn = jQuery('#board-ctn');
    var boardTop = boardCtn.offset().top;

    window.tocbot.init(Object.assign({
      tocSelector     : '#toc-body',
      contentSelector : '.markdown-body',
      linkClass       : 'tocbot-link',
      activeLinkClass : 'tocbot-active-link',
      listClass       : 'tocbot-list',
      isCollapsedClass: 'tocbot-is-collapsed',
      collapsibleClass: 'tocbot-is-collapsible',
      scrollSmooth    : true,
      includeTitleTags: true,
      headingsOffset  : -boardTop,
    }, CONFIG.toc));
    if (toc.find('.toc-list-item').length > 0) {
      toc.css('visibility', 'visible');
    }

    Fluid.events.registerRefreshCallback(function() {
      if ('tocbot' in window) {
        tocbot.refresh();
        var toc = jQuery('#toc');
        if (toc.length === 0 || !tocbot) {
          return;
        }
        if (toc.find('.toc-list-item').length > 0) {
          toc.css('visibility', 'visible');
        }
      }
    });
  });
</script>


  <script src=https://lib.baomitu.com/clipboard.js/2.0.11/clipboard.min.js></script>

  <script>Fluid.plugins.codeWidget();</script>


  
<script>
  Fluid.utils.createScript('https://lib.baomitu.com/anchor-js/5.0.0/anchor.min.js', function() {
    window.anchors.options = {
      placement: CONFIG.anchorjs.placement,
      visible  : CONFIG.anchorjs.visible
    };
    if (CONFIG.anchorjs.icon) {
      window.anchors.options.icon = CONFIG.anchorjs.icon;
    }
    var el = (CONFIG.anchorjs.element || 'h1,h2,h3,h4,h5,h6').split(',');
    var res = [];
    for (var item of el) {
      res.push('.markdown-body > ' + item.trim());
    }
    if (CONFIG.anchorjs.placement === 'left') {
      window.anchors.options.class = 'anchorjs-link-left';
    }
    window.anchors.add(res.join(', '));

    Fluid.events.registerRefreshCallback(function() {
      if ('anchors' in window) {
        anchors.removeAll();
        var el = (CONFIG.anchorjs.element || 'h1,h2,h3,h4,h5,h6').split(',');
        var res = [];
        for (var item of el) {
          res.push('.markdown-body > ' + item.trim());
        }
        if (CONFIG.anchorjs.placement === 'left') {
          anchors.options.class = 'anchorjs-link-left';
        }
        anchors.add(res.join(', '));
      }
    });
  });
</script>


  
<script>
  Fluid.utils.createScript('https://lib.baomitu.com/fancybox/3.5.7/jquery.fancybox.min.js', function() {
    Fluid.plugins.fancyBox();
  });
</script>


  <script>Fluid.plugins.imageCaption();</script>

  
      <script>
        if (!window.MathJax) {
          window.MathJax = {
            tex    : {
              inlineMath: { '[+]': [['$', '$']] }
            },
            loader : {
              load: ['ui/lazy']
            },
            options: {
              renderActions: {
                insertedScript: [200, () => {
                  document.querySelectorAll('mjx-container').forEach(node => {
                    let target = node.parentNode;
                    if (target.nodeName.toLowerCase() === 'li') {
                      target.parentNode.classList.add('has-jax');
                    }
                  });
                }, '', false]
              }
            }
          };
        } else {
          MathJax.startup.document.state(0);
          MathJax.texReset();
          MathJax.typeset();
          MathJax.typesetPromise();
        }

        Fluid.events.registerRefreshCallback(function() {
          if ('MathJax' in window && MathJax.startup.document && typeof MathJax.startup.document.state === 'function') {
            MathJax.startup.document.state(0);
            MathJax.texReset();
            MathJax.typeset();
            MathJax.typesetPromise();
          }
        });
      </script>
    

  <script  src="https://lib.baomitu.com/mathjax/3.2.2/es5/tex-mml-chtml.js" ></script>

  <script  src="/js/local-search.js" ></script>





<!-- 主题的启动项，将它保持在最底部 -->
<!-- the boot of the theme, keep it at the bottom -->
<script  src="/js/boot.js" ></script>


  

  <noscript>
    <div class="noscript-warning">博客在允许 JavaScript 运行的环境下浏览效果更佳</div>
  </noscript>
</body>
</html>
